Select Publications

Conference Abstracts

Price O; Dietze PM; Maher L; Dore GJ; Crawford S; Sutherland R; Salom C; Bruno R; Lenton S; Degenhardt L; Peacock A, 2022, 'COVID-19 pandemic experiences of people in Australia who inject drugs: Analysis of illicit drug reporting system interview data 2020-2022', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 41, pp. S115 - S115, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000862018700197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Innes H; Dore G, 2022, 'Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S560 - S560, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826275103081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Shah SHBU; Alavi M; Hajarizadeh B; Matthews G; Martinello M; Danta M; Amin J; Law M; George J; Dore G, 2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 77, pp. S302 - S302, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826275101351&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Alavi M; Valerio H; Law M; Lockart I; Danta M; Grebely J; Amin J; Hajarizadeh B; George J; Dore G, 2022, 'Incidence and risk factors of hepatitis C liver morbidity and mortality in the era of direct-acting antiviral therapies: a population-based linkage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, ENGLAND, London, Vol. 77, pp. S568 - S569, presented at International Liver Congress, ENGLAND, London, 22 June 2022 - 26 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826275103096&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carson J; Dore G; Lloyd A; Grebely J; Byrne M; Cunningham EB; Amin J; Vickerman P; Martin N; Treloar C; Matthews G; Hajarizadeh B, 2022, 'Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study', in Journal of Hepatology, Elsevier BV, Vol. 77, pp. S565 - S565, http://dx.doi.org/10.1016/s0168-8278(22)01451-9

Lockart I; Hin Yeo MG; Hajarizadeh B; Dore G; Danta M, 2022, 'Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis', in Journal of Hepatology, Elsevier BV, Vol. 77, pp. S561 - S562, http://dx.doi.org/10.1016/s0168-8278(22)01445-3

Farrell M; Shahbazi J; Byrne M; Larance B; Lintzeris N; Nielsen S; Grebely J; Shanahan M; Lancaster K; Dore GJ; Ali R; Dunlop AJ; Rodgers C; Degenhardt L, 2021, 'AN OPEN-LABEL, MULTICENTRE, SINGLE-ARM TRIAL OF MONTHLY INJECTIONS OF EXTENDED RELEASE BUPRENORPHINE IN PEOPLE WITH OPIOID USE DISORDER: THE COLAB STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S71 - S72, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Price O; Dietze PM; Maher L; Dore GJ; Trent M; Sutherland R; Karlsson A; Uporova J; Chandrasena U; Gibbs D; Swanton R; Salom C; Lenton S; Bruno R; Degenhardt L; Farrell M; Peacock A, 2021, 'COVID-19 VACCINE HESITANCY AMONG AUSTRALIANS WHO USE DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S120 - S120, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200293&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Farrell M; Shahbazi J; Byrne M; Larance B; Lintzeris N; Nielsen S; Grebely J; Shanahan M; Lancaster K; Dore GJ; Ali R; Dunlop AJ; Rodgers C; Degenhardt L, 2021, 'OVERVIEW AND FINDINGS OF THE COLAB STUDY: AN OPEN-LABEL IMPLEMENTATION STUDY OF SUBLOCADE TREATMENT IN SPECIALIST AND PRIMARY CARE SETTINGS IN AUSTRALIA', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 40, pp. S25 - S25, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000715073200062&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lockart I; Yeo M; Hajarizadeh B; Dore GJ; Danta M, 2021, 'Hepatocellular carcinoma occurrence after hepatitis C virus cure among patients with advanced fibrosis or cirrhosis: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 36, pp. 40 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693377800070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lazarus J; Picchio C; Byrne C; Crespo J; Colombo M; Cooke G; Dore G; Grebely J; Ward J; White T; Dillon J, 2021, 'A global systematic review of efforts to accelerate the elimination of hepatitis C virus (HCV) through micro-elimination', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 75, pp. S661 - S662, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000667753801295&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

He S; Alavi M; Hajarizadeh B; Grebely J; Law M; Amin J; George J; Danta M; Dore G, 2021, 'comparison of hbv-related hcc incidence between entecavir and tenofovir treated cohorts: a population-based study', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 75, pp. S515 - S516, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000667753801051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hosseini-Hooshyar S; Alavi M; Martinello M; Matthews G; Dore G, 2021, 'Evaluation of the HCV cascade of care among people with HIV/hepatitis C co-infection in New South Wales, Australia: a data linkage study', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 24, pp. 19 - 19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000713652900036&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lockart I; Hajarizadeh B; Alavi M; Davison S; Section EP; Levy MT; George J; Dore GJ; Danta M, 2020, 'Sustained virological response before hepatitis C-related hepatocellular carcinoma diagnosis is associated with improved survival', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 35, pp. 53 - 54, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000589476200075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kwon JA; Dore G; Hajarizadeh B; Guy R; Gray RT, 2020, 'Evidence of declining HCV transmission in Australia following scale-up of direct acting antiviral therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vol. 73, pp. S606 - S606, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587002012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Conway B; Litwin AH; Dalgard O; Shibolet O; Nahass RG; Altice F; Gane EJ; Luetkemeyer A; Peng C-Y; Iser D; Gendrano IN; Kelly M; Hwang P; Asante-Appiah E; Barr E; Robertson MN; Platt H; Dore G, 2019, 'DRUG USE AND REINFECTION DURING AND FOLLOWING HCV TREATMENT WITH ELBASVIR/GRAZOPREVIR AMONG PATIENTS RECEIVING OPIOID AGONIST THERAPY: FINAL RESULTS FROM THE CO-STAR STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 955A - 956A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503272&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

He S; Dore G; Law M; Heahter V; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'IMPROVED SURVIVAL FOLLOWING HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA DIAGNOSIS IN THE DIRECT-ACTING ANTIVIRAL THERAPY ERA IN NEW SOUTH WALES, AUSTRALIA', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 906A - 906A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503195&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Matthews G; Bhagani S; Van der Valk M; Rockstroh JK; Kim AY; Thurnheer C; Feld JJ; Bruneau J; Gane EJ; Hellard M; Grebely J; Applegate T; Marks P; Martinello M; Petoumenos K; Dore G, 2019, 'SHORT COURSE DURATION SOFOSBUVIR/VELPATASVIR IS INFERIOR TO STANDARD DURATION THERAPY IN THE TREATMENT OF RECENTLY ACQUIRED HCV INFECTION: RESULTS FROM REACT STUDY', in HEPATOLOGY, WILEY, MA, Boston, Vol. 70, pp. 1487A - 1488A, presented at 70th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, MA, Boston, 08 November 2019 - 12 November 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000500824000056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Reid H; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J, 2019, 'HEPATITIS C VIRUS REINFECTION FOLLOWING ANTIVIRAL TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S50 - S51, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kearley J; Gilliver R; Lothian R; Cunningham EB; Dore GJ; Read P, 2019, 'MAXIMISING ADHERENCE TO DIRECT-ACTING ANTI-VIRALS FOR HEPATITIS C AMONG STREET-BASED AND MARGINALISED CLIENTS USING AN OPIOID AGONIST TREATMENT PROGRAM: THE RESULTS OF DAILY DOSING', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S59 - S60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100150&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hajarizadeh B; Marshall AD; Grebely J; Dore GJ; Treloar C; Corry A; Hayllar J; Byrne J, 2019, 'SYMPOSIUM: ENHANCING HEPATITIS C CARE AMONG PEOPLE WHO INJECT DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S8 - S9, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kearley J; Gilliver R; Lothian R; Dore GJ; Read P, 2019, 'WHEN TREATMENT ACCESS DOES NOT EQUAL TREATMENT INITIATION: AN ANALYSIS OF CLIENTS WHO DO NOT INITIATE DIRECT ACTING ANTIVIRALS FOR HEPATITIS C', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S60 - S60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100151&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

He S; Hajarizadeh B; Lockart I; Alavi M; Danta M; Dore G, 2019, 'Effectiveness of direct-acting antiviral therapy for hepatitis C among people with hepatocellular carcinoma: A systematic review and meta-analysis', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 71 - 72, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

He S; Dore G; Law M; Valerio H; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'Improved survival after hepatitis C-related hepatocellular carcinoma diagnosis in the direct-acting antiviral therapy era in New South Wales, Australia', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 82 - 82, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100132&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E733 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hooshyar SH; Martinello M; Yee J; Bartlett S; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Marks P; Applegate T; Dore G; Matthew G, 2019, 'Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E734 - E734, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703225&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'Reinfection following successful HCV DAA therapy among people with recent injecting drug use', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E732 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703222&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Valerio H; Alavi M; Silk D; Treloar C; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Degenhardt L; Dore G; Grebely J, 2019, 'Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage study', in JOURNAL OF HEPATOLOGY, ELSEVIER, AUSTRIA, Vienna, Vol. 70, pp. E42 - E42, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), AUSTRIA, Vienna, 10 April 2019 - 14 April 2019, http://dx.doi.org/10.1016/S0618-8278(19)30076-3

Grebely J; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Conway B; Nahass R; Altice F; Luetkemeyer A; Peng C-Y; Iser D; Gendrano IN; Huang H-C; Kelly MM; Hwang P; Barr E; Robertson MN; Platt H; Dore G, 2018, 'HCV Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Patients on Opioid Agonist Therapy: Co-STAR Part B', in HEPATOLOGY, WILEY, CA, San Francisco, Vol. 68, pp. 35A - 35A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, CA, San Francisco, 09 November 2018 - 13 November 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000446020500053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Salazar-Vizcaya L; Boettiger DC; Dore GJ; Gray R; Law M; Rauch A; Lea T; Matthews G, 2018, 'Will hepatitis C transmission be eliminated by 2025 among HIV-positive men who have sex with men in Australia?', in JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, JOHN WILEY & SONS LTD, Vol. 21, pp. 66 - 66, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440002700139&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dore G; Hezode C; Kwo P; Sperl J; Hwang P; Long J; Talwani R; Robertson M; Haber B, 2018, 'Efficacy and safety of elbasvir/ grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, Vol. 25, pp. 56 - 57, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000092&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yee J; Dore GJ; Hanson J; Iser D; Danta M; Shaw D; Read P; Balcomb A; Post J; Faros J; Montebello M; Collie P; Hallinan R; Cooper L; Marks P; Hajarizadeh B; Matthews GV, 2018, 'High efficacy of HCV therapy following universal DAA access in Australia: the REACH-C cohort', in JOURNAL OF VIRAL HEPATITIS, WILEY, CANADA, Toronto, Vol. 25, pp. 54 - 54, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), CANADA, Toronto, 14 June 2018 - 17 June 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dalgard O; Grebely J; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and Velpatasvir for Hepatitis C Virus Infection in People with Recent Injecting Drug Use (Simplify): An Open-Label, Single-Arm, Phase 4, Multicentre Trial', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 14 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440974900004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dalgard O; Grebely J; Feld JJ; Wyles D; Sulkowski M; Ni L; Llewellyn J; Soyemi T; Sajed N; Stamm LM; Hyland RH; McNally J; Brainard DM; Jacobson I; Zeuzem S; Bourliere M; Foster G; Afdhal N; Dore GJ, 2018, 'Sofosbuvir-Based Direct-Acting Antiviral Therapies for Hcv in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 13 - 14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440974900003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Martinello M; Bartlett S; Dore G; Bopage R; Finlayson R; Baker D; Bloch M; Doyle J; Shaw D; Hajkowicz K; Read P; Filep E; Lin L; Yee J; Applegate T; Hellard M; Matthews G, 2018, 'Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia', in Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia, Paris, France, presented at THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, 11 April 2018 - 15 April 2018

Hezode C; Kwo P; Sperl J; Dore G; Hwang P; Long J; Talwani R; Robertson M; Haber B, 2018, 'Efficacy and safety of Elbasvir/Grazoprevir in women infected with hepatitis C virus genotype 1 or 4 and co-administered oral contraceptives or hormone replacement therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, FRANCE, Paris, Vol. 68, pp. S264 - S265, presented at International Liver Congress (ILC), FRANCE, Paris, 11 April 2018 - 15 April 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000461068601134&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Martinello M; Cerrone M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Schoolmeesters A; Grebely J; Nelson M; Matthews GV, 2018, 'TARGET3D: high efficacy of 8 weeks paritaprevir/ritonavir/ombitasvir and dasabuvir among people with recent genotype 1 HCV infection', in HIV MEDICINE, WILEY, Vol. 19, pp. S151 - S152, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000430174700440&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin AH; Dillon JF; Read P; Gane ED; Dore GJ, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTING DRUG USE: THE SIMPLIFY STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 36, pp. 34 - 34, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Foster GR; Grebely J; Sherman KE; Wang S; Dore GJ; Baumgarten A; Conway B; Jackson DF; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar HI; Alami NN; Dumas EO; Hu Y; Mensa FJ, 2017, 'Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1-6 and Recent Drug Use', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 636A - 637A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089801323&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Martinello M; Bhagani S; Gane EJ; Orkin C; Cooke G; Kulasegaram R; Shaw D; Hellard M; Tu E; Filep E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews G, 2017, 'Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study', in HEPATOLOGY, WILEY, DC, Washington, Vol. 66, pp. 574A - 575A, presented at 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, DC, Washington, 20 October 2017 - 24 October 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000412089801215&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S495 - S496, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31388-0

Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer CM; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S513, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601271&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Foster GR; Gane E; Asatryan A; Asselah T; Ruane PJ; Pol S; Poordad F; Stedman CA; Dore G; Roberts SK; Kaita K; Vierling J; Vargas HE; Kort J; Lin C-W; Liu R; Ng T; Mensa F, 2017, 'ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S33 - S33, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30326-4

Lamoury FM; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty GA; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S710 - S710, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31901-3

Marshall AD; Nielsen S; Cunningham EB; Aghemo A; Alho H; Backmund M; Bruggmann P; Dalgard O; Flisiak R; Foster G; Gheorghe L; Goldberg D; Goulis I; Hickman M; Hoffmann P; Jancoriene L; Jarcuska P; Kaberg M; Makara M; Maimets M; Marinho R; Maticic M; Norris S; Olafsson S; Ovrehus A; Pawlotsky J-M; Pocock J; Robaeys G; Roncero C; Simonova M; Sperl J; Tait M; Tolmane I; Tomaselli S; van der Valk M; Vince A; Dore GJ; Lazarus JV; Grebely J, 2017, 'Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S95 - S96, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30450-6

Grebely J; Jacobson IM; Kayali Z; Verna EC; Shiffman ML; Hyland RH; Stamm LM; Huang KC; Brainard DM; McHutchison JG; Pol S; Chung RT; Bernstein DE; Dore G, 2017, 'SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S513 - S514, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601272&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bartlett SR; Grebely J; Eltahla AA; Reeves JD; Howe A; Miller V; Bull RA; Ceccherini-Silberstein F; Douglas MW; Dore GJ; Harrington P; Lloyd AR; Jacka B; Matthews GV; Wang GP; Pawlotsky J-M; Feld JJ; Schinkel J; Garcia F; Lennerstrand J; Applegate TL, 2017, 'Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S323 - S323, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30970-4

Kwon AJ; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued', in Journal of Virus Eradication, Elsevier BV, Vol. 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30895-5

Dore G; Grebely J; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng C-Y; Conway B; Iser DM; Huang H-C; Gendrano IN; Kelly MM; Hwang P; Robertson M; Wahl J; Barr E; Platt HL, 2016, 'HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR Three Year Follow-up Study', in HEPATOLOGY, WILEY, MA, Boston, Vol. 64, pp. 431A - 431A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), MA, Boston, 11 November 2016 - 15 November 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802139&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Marshall AD; Krahe M; Erratt A; Telenta J; Treloar C; Jones SC; Adey S; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop AJ; Applegate TL; Lamoury F; Mowat Y; Jauncey M; Read P; Gilliver R; Smith J; Collie T; Dore GJ, 2016, 'A LIVER HEALTH PROMOTION INTERVENTION INTEGRATING NON-INVASIVE LIVER DISEASE SCREENING IN DRUG AND ALCOHOL SETTINGS: THE LIVERLIFE STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 35, pp. 40 - 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398381500109&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1


Back to profile page